[Source](https://github.com/mm80843/T3.5/blob/main/docs/index.md) -- [Benef](https://github.com/mm80843/T3.5/tree/main/docs/Benef/index.md) 

# Benef: __Increased testing capacity and throughput__ (PBN__Benef_1019)

## Property: has_Beneficiary

* [healthcare systems](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_193.md)
* [public health officials](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_310.md)

## Property: has_BenefSource

* [daughton_wastewater_2020](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_213.md)

## Property: has_BenefReturn

* [Private investors investing in pooled-sample analysis technologies can benefit from increased demand for testing services, potential contracts with healthcare systems, and financial returns from the implementation of these technologies.](https://github.com/mm80843/T3.5/blob/main/docs/BenefReturn/PBN__BenefReturn_1140.md)

## Property: has_BenefDetails

Pooled-sample analysis can greatly increase testing capacity and throughput, allowing for more efficient and widespread testing of populations.

